Text messaging program to reduce HIV risk among dental patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a text message-based intervention aimed at reducing HIV risk among dental patients at four community health centers. Participants will be randomly assigned to receive either text messages focused on HIV prevention or general wellness. The study will first conduct a feasibility pilot with a small group before enrolling a larger cohort of 266 participants. The intervention targets individuals who are HIV-negative but have at least one risk factor for HIV, and recruitment will be conducted in both English and Spanish.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Give informed consent and document consent via a signed and dated informed consent form in REDCap
* Willing to comply with all study procedures and be available for the duration of the study
* Be able to read either in English or Spanish
* Be a dental clinic patient of record at one of our participating community health centers
* Has at least one risk factor for HIV defined as self-report of at least one of the following: Men who have sex with men; multiple sex partners, or intravenous drug use

Exclusion Criteria:

* Self-report of having HIV infection
* Participating in another HIV study or another text message study
* A woman who reports having sex exclusively with women
* Does not have a mobile phone or other device which can receive text messages from Agile Health
* Does not have unlimited texting on their mobile plan
* Has not used any type of text messaging at least once in the past month
* Single item literacy screening score of 2 or below.

Where it's running

• South End Community Health Center
  Boston, Massachusetts, United States Recruiting
• East Boston Neighborhood Health Center
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Michelle Henshaw, DDS, MPH — Boston University Goldman School of Dental Medicine
• Study coordinator: Michelle Henshaw, DDS, MPH
• Email: mhenshaw@bu.edu
• Phone: :617-358-6111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

• Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART

  This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.

  Recruiting at 19 sites Phase 3 Gilead Sciences · San Francisco, California and 18 other locations · NCT07682961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.